Table 1 Baseline characteristics of early RA patients and healthy controls.

From: Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response

 

Early RA

Healthy controls

Patients, n

52

52

Males/females, n (%)

16/36 (30.8/69.2)

16/36 (30.8/69.2)

Age, years

50.8 ± 16.1

50.5 ± 15.3 (p = 0.926)

BMI, kg/m2

25.4 ± 4.6

26.2 ± 4.2 (p = 0.337)

CRP, mg/l

18.9 ± 24.0

2.7 ± 3.8 (p < 0.001)

ESR, mm/1st hour

34.0 ± 24.0

–

DAS28

5.5 ± 1.4

–

CDAI

30.6 ± 16.1

–

SDAI

32.5 ± 17.5

–

Disease duration, months

 < 6

–

RF positivity, n (%)

31 (59.6)

–

Anti-CCP positivity, n (%)

27 (51.9)

–

csDMARDs/GCs, n (%)

51/47 (98.1/90.4)

–

Methotrexate, n (%)

43 (82.7)

–

Sulfasalazine, n (%)

7 (13.5)

–

Leflunomide, n (%)

1 (1.9)

–

  1. Anti-CCP anti-cyclic citrullinated peptide antibodies, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, DAS28 28-joint Disease Activity Score, ESR erythrocyte sedimentation rate, GCs glucocorticoids, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index. Data are presented as the mean ± the SD.
Back to article page